ABPI

Over twenty pharma companies have rejected the UK government’s proposed changes to the statutory scheme for branded medicines, the latest move in an ongoing disagreement between the government and industry. According to the Association of the British Pharmaceutical industry (ABPI), the “radical plans” are “unworkable”. And will be “highly damaging to UK life sciences and […]

Following lengthy negotiations, the UK government has announced that the UK will be participating as a fully associated member of Horizon Europe for the remaining life of the programme to 2027. UK researchers can now apply for grants and bid to take part in projects under the Horizon programme. They will also be able to […]

The pharmaceutical industry continues to maintain strong levels of public trust and favourability in the UK, according to data from the Association of the British Pharmaceutical Industry (ABPI). Opinions showed consistent recognition of the sector’s support for the NHS, with 67% of respondents saying the industry is committed to developing new medicines to meet patient […]

The UK government has announced up to £210 ($267) million of funding to partner with countries across Asia and Africa to tackle antimicrobial resistance (AMR) and reduce the threat posed to the UK. The announcement follows the £39 ($48) million investment through the Global AMR Innovation Fund (GAMRIF) in May. The money is intended to pay […]

The second quarter of 2023 has seen steady growth in financing activity for the UK’s life sciences sector, according to new data released by the BioIndustry Association (BIA) and Clarivate. The positive news comes soon after industry figures welcomed recent announcements to unlock new sources of capital in the City of London. Last month, the […]

International investors are abandoning UK life sciences as excessive revenue clawback rates start to bite, according to the latest Life Sciences Competitiveness Indicators published by the government1. The UK saw a substantial drop in the estimated value of inward life sciences foreign direct investment (FDI) in 2022 compared to 2021, falling to £1.9 billion ($2.5 […]

The UK spends less on medicines, has a lower adoption of new drugs and poorer health outcomes compared to other similar countries, according to a new report. The King’s Fund report, commissioned by the Association of the British Pharmaceutical Industry (ABPI), gives the UK’s NHS a mixed bill of health across a range of outcome […]

The Prescription Medicines Code of Practice Authority (PMCPA), a self-regulatory body which administers the Association of the British Pharmaceutical Industry (ABPI) Code of Practice for the Pharmaceutical Industry, have opened cases against Leo Pharma, AstraZeneca and Daiichi Sankyo for bringing discredit upon, and reducing confidence in, the pharmaceutical industry. AstraZeneca   AstraZeneca was ruled in breach […]

The UK government will invest up to £39 ($48) million in antimicrobial resistance (AMR) research through the Global AMR Innovation Fund (GAMRIF). The funding includes up to £25 ($30.9) million awarded to support the early development of new antibiotics, vaccines, rapid diagnostics and other products to combat life-threatening drug-resistant infections. The money will bolster the […]

A series of new measures will be introduced by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to make it faster and easier to gain approval and run clinical trials in the UK. These changes represent the biggest overhaul in UK clinical trials regulation in over 20 years and are designed to make the […]

Novo Nordisk has been suspended as a member of the Association of the British Pharmaceutical Industry (ABPI) for two years due to serious breaches of the ABPI Code of Practice. This is the eighth occasion in the past 40 years the ABPI Board has issued such a significant sanction. The ABPI says the action has […]

The ABPI Board has confirmed that Susan Rienow, UK Country President of Pfizer, will be the next President of the Association of the British Pharmaceutical Industry (ABPI).   Rienow was appointed as ABPI Vice-President in September 2022 and will formally take up her role as President in May 2023.   As President, Rienow will lead the ABPI Board […]

Collaborative working between the NHS and industry could reduce variations in uptake of innovative treatments across the UK, a joint report from NHS Confederation and ABPI argues.   Analysis from the report has shown a significant variation in access to innovative medicines for patients across the UK and showed that uptake of new treatments in these […]

AbbVie and Eli Lilly have left the voluntary medicines pricing agreement in protest over what they describe as “increasingly punitive revenue clawbacks”.  The companies have left the UK’s Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), a long-standing agreement between government and industry with roots going back to the foundation of the NHS.  As […]

The UK government has announced its future strategy for batch testing of medicinal products.  The new strategy means that the UK will continue to recognise batch testing from the EU/EEA, rather than insisting on duplicative batch testing operations.  Post-BREXIT, the pharmaceutical industry urged the UK and the EU to sign a Mutual Recognition Agreement (MRA) […]

Developing new antibiotics is essential to winning the fight against resistant infections, the Association of the British Pharmaceutical Industry (ABPI) has said.  The comments come ahead of World Antimicrobial Awareness Week (18-24 November), which aims to improve the awareness and understanding of antimicrobial resistance (AMR).   The event seeks to encourage best practices among the public, health […]